Nordic Health Report - Chronic Migraine

CGRP is third line or later treatment that is offered to patients with chronic migraines who have experienced treatment failure in previous prophylactic treatments with antihypertensive and antiepileptic drugs. There are currently three treatments in the market. Consumption data shows that usage of CGRP biologic treatments differ greatly across countries. While the growth in usage has strongly accelerated in Norway since early 2020, the trend in the other three countries is a more stagnant development.